DBV Technologies S.A. (EPA:DBV)
1.518
-0.026 (-1.68%)
Apr 25, 2025, 5:38 PM CET
DBV Technologies Revenue
In the year 2024, DBV Technologies had annual revenue of $4.15M USD, down -73.61%. DBV Technologies had revenue of $511.00K in the quarter ending December 31, 2024, a decrease of -94.24%.
Revenue
$4.15M
Revenue Growth
-73.61%
P/S Ratio
51.75
Revenue / Employee
$37.74K
Employees
110
Market Cap
207.48M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
EssilorLuxottica Société anonyme | 26.51B |
Sanofi | 45.17B |
Sartorius Stedim Biotech | 2.86B |
bioMérieux | 3.98B |
Eurofins Scientific SE | 6.95B |
Ipsen | 3.57B |
Virbac | 1.40B |
emeis Société anonyme | 5.64B |
DBV Technologies News
- 14 days ago - DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - GlobeNewsWire
- 4 weeks ago - Why DBV Technologies (DBVT) Stock Is Skyrocketing - Benzinga
- 4 weeks ago - DBV Technologies ADRs Rise After Up to $306.9M in New Financing - Market Watch
- 4 weeks ago - DBV Technologies announces up to $307M financing to advance Viaskin Peanut program - Seeking Alpha
- 4 weeks ago - DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved - GlobeNewsWire
- 4 weeks ago - DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results - GlobeNewsWire
- 2 months ago - DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - GlobeNewsWire
- 3 months ago - Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - GlobeNewsWire